
Implementation of long-acting injectable cabotegravir for PrEP in Brazil with Beatriz Grinsztejn
Daily oral PrEP is highly effective, but taking a pill consistently can be challenging. Could long-acting injectable cabotegravir help close gaps in HIV prevention? What would it take to make it available through Brazil’s public health system? In this episode, the authors discuss the ImPrEP CAB Brasil study, which evaluated same-day access to injectable PrEP across six Brazilian cities, explore what the study found about PrEP coverage, participant choice, and delivering CAB-LA in routine care, as well as the questions that remain for equitable access and scale-up.
Click here to read the full article:
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00201-8/fulltext
More episodes from "The Lancet HIV in conversation with"



Don't miss an episode of “The Lancet HIV in conversation with” and subscribe to it in the GetPodcast app.








